Article Text

Download PDFPDF

2022-RA-903-ESGO Prophylactic radical fimbriectomy with delayed oophorectomy in women with a high risk of developing an ovarian carcinoma: results of a prospective phase 2 national study
  1. Eric Leblanc1,
  2. Fabrice Narducci1,
  3. Houssein El Hajj1,
  4. Gwenael Ferron2,
  5. Audrey Mailliez1,
  6. Jean-Yves Charvolin3,
  7. Calos Martinez Gomez1,
  8. Frederic Guyon4,
  9. Anne Sophie Lemaire5,
  10. Virginie Fourchotte6,
  11. Alicia Probst7,
  12. Eric Lambaudie8,
  13. Emmanuelle Tresch7,
  14. Isabelle Fournier9,
  15. Veronique Vaini-Cowen10,
  16. Francois Golfier11,
  17. Christophe Pomel12,
  18. Frederic Caquant13,
  19. Pierre Collinet14,
  20. Sebastien Gouy15,
  21. Yves Fouche16,
  22. Agathe Crouzet17,
  23. Marie Cecile Le Deley7 and
  24. Delphine Hudry1
  1. 1Gynecologic Oncology, Oscar Lambret Cancer Center, Lille, France
  2. 2Centre Claudius Regaud, Toulouse, France
  3. 3Clinique du Bois Lille France, Lille, France
  4. 4Institut Jean-Alban Bergonié, Bordeaux, France
  5. 5Pathology, Oscar Lambret Cancer Center, Lille, France
  6. 6Institut Curie, Paris, France
  7. 7Biostatistics, Oscar Lambret Cancer Center, Lille, France
  8. 8Institut Paoli Calmettes, Marseille, France
  9. 9INSERM U1192, Université de Lille, France, Lille, France
  10. 10Polyclinique du Parc Rambot, Aix en Provence, France
  11. 11Hospices civils de Lyon, Lyon, France, Lyon, France
  12. 12Centre Jean Perrin, Clermont-Ferrand, France
  13. 13Hôpital privé de Villeneuve d’Ascq, Lille, France
  14. 14Hôpital Jeanne de Flandre, Lille, France
  15. 15Institut Gustave Roussy, Villejuit, France
  16. 16Centre Antoine Lacassagne, Nice, France
  17. 17Centre Henri Becquerel, Rouen, France


Introduction/Background Risk-reducing salpingo-oophorectomy is the gold standard for prophylaxis of ovarian cancer in high-risk women. Due to significant adverse effects, 20–30% of women delay or refuse early oophorectomy. We proposed a new two-step risk-reducing procedure: radical fimbriectomy followed by delayed oophorectomy, which is evaluated by the current RF/DO Phase 2 trial (NCT01608074).

Methodology Pre-menopausal women ≥35 years with HBOC who refused RRSO were offered to participate in RF/DO trial. All surgical specimens underwent the SEE-FIM protocol. The primary endpoint was the cumulative incidence of ovarian/pelvic invasive carcinoma. Secondary endpoints were morbidity, surgical specimen abnormalities, menopause, breast cancer (BC) occurrence, and secondary oophorectomy.

Results From January 2012 to October 2014, 121 patients underwent RF, 51 were performed in the ambulatory setting. Occult neoplasia was found in two cases, with one tubal HGSC. Two patients experienced grade-1 intraoperative complications. No early or delayed grade≥3 postoperative complications. After 7.3 years of median follow-up, no cases of pelvic invasive cancer were noted. 3/52 patients developed de novo BC. One BRCA1-mutated woman delivered safe twins. 25 patients underwent menopause including 15 who had received chemotherapy for BC: 23 before DO and two did not undergo DO. Overall, 46 women underwent DO, 23 after menopause, 3 after the age of 51, 8 for personal decision, and 11 for other medical reasons. No abnormalities were found in any DO specimens.

Conclusion RF/DO appears a safe and well-tolerated risk-reducing approach that avoids early menopause for HBOC patients. Furthermore, due to the absence of abnormalities at mesothelio-Müllerian junctions, simple total bilateral salpingectomy may replace RF

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.